Skip to main content

Michael J. Fox Foundation Archives

Vanderbilt licenses compound to Nashville’s Appello to advance Parkinson’s therapies

Jul. 12, 2018—Vanderbilt University has signed a licensing agreement with Nashville-based start-up Appello Pharmaceuticals, Inc. to advance novel compounds developed by researchers in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) for the treatment of Parkinson’s disease.

Read more


Amish aid study of Parkinson genetics

Nov. 11, 2013—Amish populations are valuable for genetic research because of their isolation, shared ancestry and homogeneous lifestyles.

Read more


VU, Bristol-Myers to collaborate on Parkinson’s therapies

Sep. 21, 2012—Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

Read more


Neuroscience drug discovery center opens at Vanderbilt

Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.

Read more


Recent Stories from VUMC News and Communications Publications

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

Vanderbilt Medicine

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

VUMC campus

VUMC campus

Vanderbilt University School of Medicine entrance

Vanderbilt University School of Medicine entrance

Vanderbilt University Adult Hospital with helipad

Vanderbilt University Adult Hospital with helipad

more